Society for Cardiovascular Angiography and Interventions (SCAI)
1100 17th Street NW, Suite 330
Washington
DC
20036
USA
202.741.9854
[email protected]
http://www.scai.org

Related Content

Multi-center study explores new treatment for heart failure patients with preserved and reduced ejection fraction
News | Heart Failure
No-implant Interatrial Shunt Device to Treat Heart Failure Patients Reveals Promising Multi-center Clinical Data

May 20, 2022 — Results from early clinical evaluation of the Alleviant System to treat heart failure patients with ...

Home May 20, 2022
arrow
New Analysis Shows the Evolution of Intervention Techniques in Chronic Total Occlusion Patients
News | Chronic Total Occlusion (CTO)
International Chronic Total Occlusion Percutaneous Coronary Intervention Registry Finds Increasing Procedural Success

May 20, 2022 — A new analysis of PROGRESS-CTO (PROspective Global REgiStry for the Study of Chronic Total Occlusion ...

Home May 20, 2022
arrow
Three years ago a study raised concerns that paclitaxel-coated devices may cause increased mortality in peripheral artery disease patients. However, numerous studies now show there is no risk of increased mortality. The most recent study is the SAFE-PAD study presented at SCAI22.
News | Peripheral Artery Disease (PAD)
New Longterm Data of Paclitaxel Devices Continues to Show No Increased Mortality Compared to Non-drug Coated Devices

May 20, 2022 — New long-term data from the Safety Assessment of Femoropopliteal Endovascular Treatment With PAclitaxel ...

Home May 20, 2022
arrow
The Medtronic Harmony transcatheter pulmonary valve (TPV) system offers a less invasive treatment option for patients with a congenital heart defect irregularity in their right ventricular outflow tract (RVOT) that requires a pulmonary valve placement to restore valve function. 
News | Heart Valve Technology
First Intermediate to Long-term Study of the Harmony Transcatheter Pulmonary Valve System Validates Safety and Efficacy

May 19, 2022 — A study of 1-year outcomes in the largest cohort to date of Harmony transcatheter pulmonary valve (TPV) ...

Home May 19, 2022
arrow
First multi-center, randomized controlled study provides the largest long-term evidence for the treatment of heavily calcified femoropopliteal lesions
News | Peripheral Artery Disease (PAD)
Disrupt PAD III Trial Demonstrates Safety and Effectiveness of Intravascular Lithotripsy for Peripheral Artery Calcification

May 19, 2022 — One year outcomes from the Disrupt PAD III Trial comparing intravascular lithotripsy (IVL) with a drug ...

Home May 19, 2022
arrow
The latest analysis from The North American COVID-19 STEMI (NACMI) was presented today as late-breaking clinical research at the Society for Cardiovascular Angiography & Interventions (SCAI) 2022 Scientific Sessions.
News | STEMI
International COVID-19 Registry Finds Significant Increased Risk of In-hospital Mortality for STEMI Patients with COVID-19 Compared to Pre-pandemic

May 19, 2022 — The latest analysis from The North American COVID-19 STEMI (NACMI) was presented today as late-breaking ...

Home May 19, 2022
arrow
30-day findings from the DIPRA study demonstrate distal radial artery access poses no increased hand dysfunction risk
News | Radial Access
Novel Distal Radial Access for Cardiac Catheterization Shown as a Safe Strategy Compared to Conventional Radial Access

May 19, 2022 — Initial findings from the Distal versus Proximal Radial Artery Access for Cardiac Catheterization and ...

Home May 19, 2022
arrow
After two years of virtual meetings, the Society for Cardiovascular Angiography & Interventions (SCAI) looks forward to welcoming more than 2,000 attendees to an exciting, fully live meeting in Atlanta, May 19-22.
News | SCAI
SCAI22 Scientific Sessions

May 10, 2022 — After two years of virtual meetings, the Society for Cardiovascular Angiography & Interventions (SCAI) ...

Home May 10, 2022
arrow
Figure 1Recommended Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. ∗While not marketed in the United States, DCBs are available for clinical use in Canada, with 1-3 months of DAPT recommended. DAPT = dual antiplatelet therapy; LD, limited data. Reprinted from Capodanno D, Alfonso F, Levine GN, Valgimigli M, Angiolillo DJ. ACC/AHA versus ESC guidelines on dual antiplatelet therapy: JACC guideline comparison. J Am Coll Cardiol. 2018;72(23 Pt A):2915-2931, with permission from
News | Womens Cardiovascular Health
SCAI Releases Expert Consensus on Gender-specific Considerations in Myocardial Revascularization

February 9, 2022 — A newly released expert consensus statement on sex-specific considerations in myocardial ...

Home February 09, 2022
arrow
Videos | Cardiogenic Shock
VIDEO: Updates Made to the SCAI Cardiogenic Shock Classifications

Srihari Naidu, M.D., FACC, FAHA, FSCAI, is the director of both the cardiac cath labs and Hypertrophic Cardiomyopathy ...

Home November 16, 2021
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now